RHPS has just mentioned the above in an e-mail, they have gone up 240% today - started at 0.60 and finished up at 1.65. Look to be quite interesting.

Either they are being very cautious who they choose for a licencing partner, or a licencing agreement is not forthcoming. I would like to think that it is the former and they can't make up their minds whether to go for GSK or AZN (or a company of that calibre!).

Perhaps still a little early, but I'm starting to get itchy feet here. Have SAR got a cure? :o)
C'mon SAR, RNS in the morning PLEASE!

I hope they heard me. ;o)

Kim...your wish!...

More leaked news?...A lot of activity all of a sudden?

Lol! Interesting Tabby!

That was quite strange! I think everyone needs to ask for an RNS!

Altogether now......................Where's that RNS???!!! :o)

Did a few test sells late on, my broker consistently offered more than the stated bid price which made me think that they had wind of something positive. I shall be soooo cwoss and stamp my 'ikkle feet if I am wrong!

Kim...Last seven sessions have shown an average of around 15mil shares traded...93mil today?...must be just a coincidence. Bound to go down tomorrow...I dont think!

Also... halfway through the day only 11mil shares traded...so why the afternoon mad rush on no news?...must have been corkscrew carter...straight as a dye?

Time will tell!

Update from their website.

level 2 strong right now http://www.sareum.co.uk/base/images/pdfs/SareumMay20052011.pdf

4.2p fair value

Just sold half at >100%. Should have done so on the last up.

well done - bit early to sell yet - l2 very strong buying but understand why some going too early - gl

could be a 50% + peak

Gibby - I have more than my original stake back and am happy to let the remainder run - a policy I try to adhere to with "tiddlers".

good policy

profit takers about right now

Looks like Sar's running out of steam?

The boilers been stoked!...

Preclinical Development Candidate Selected for Chk1 Inhibitor Programme
Share this article
print


TIDMSAR

(AIM: SAR) 15 August 2011



SAREUM HOLDINGS PLC ("Sareum")

Preclinical Development Candidate Selected for Chk1 Inhibitor Programme

Sareum, the specialist cancer drug discovery business, The Institute of Cancer
Research ("the ICR") and Cancer Research UK's commercial arm, Cancer Research
Technology Limited ("CRT") are pleased to announce the selection of a

preclinical development candidate from their joint research collaboration.

The joint research collaboration targets Chk1 (Checkpoint Kinase 1). Chk1 is
important in controlling a cancer cell's response to DNA damage, which may be a

consequence of the cancer itself, or intentionally caused by chemotherapy or
radiotherapy.

Preclinical model studies carried out at the Cancer Research UK Cancer
Therapeutics Unit at the ICR demonstrate that the Chk1 candidate, dosed via the

oral route, in combination with the chemotherapeutics gemcitabine or irinotecan
significantly reduces cancer growth rates compared to treatment with the same

dose of chemotherapeutic without the Chk1 inhibitor.

Further preclinical studies demonstrate the potential for the collaboration Chk1
development candidate to reduce tumour growth when given as a sole treatment in

models of certain cancer types that are believed to be dependent on Chk1 for
survival.

Sareum's CEO, Dr Tim Mitchell, commented: "The selection of a preclinical
development candidate is a major milestone for the collaboration that will

significantly enhance the licensing package. Our research indicates that the
selectivity and oral dosing properties of this candidate give it a competitive
advantage."

Professor Paul Workman, Director of the Cancer Research UK Cancer Therapeutics

Unit at the ICR, said: "The significant progress made so far is very pleasing
and highlights the value of partnerships between industry and academic drug

discovery groups like ours. There is further important development work to be
done so that patients can one day benefit from these drugs, and we look forward
to the progress of the compound towards the clinic."


Dr Philip Masterson, Associate Director at Cancer Research Technology, said: "We
are working to select the right commercial partner to take the Chk1 programme
into clinical development. Our ultimate aim is that one day, this drug will

become available to treat a range of cancers and save more lives from the

disease.

Our scientists have shown that this drug is promising in preclinical studies,
and we hope further research will prove that it can be used on its own or
alongside chemotherapy and radiotherapy to destroy cancer cells in patients."


For Further Information:

Sareum Holdings pl

No 1 on the LSE top listhot enough?

Certainly a step in the right direction Tabby. "One small step.........." etc!

Sareum Holdings plc

("Sareum" or "the Company")

Final Results

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery business,
is pleased to announce its final results for the year ended 30 June 2011.

Operational Highlights
* Significant progress on the two most advanced cancer programmes including
positive in-vivo efficacy data from Chk1 and Aurora+FLT3 programmes
* Nomination of preclinical development candidate for Chk1 in August 2011

Financial Highlights
* GBP950,000 (before expenses) raised by way of three share placings
* Cash at bank and in hand of GBP871,000; sufficient cash resources for
foreseeable future, based on current spending levels
* Loss on ordinary activities (after taxation) GBP568,000 (2010: GBP569,000 loss)
in line with expectations

Tim Mitchell, Chief Executive Officer of the Company, said: "The announcement of
two successful in-vivo efficacy studies, and the selection of a preclinical
development candidate, bring Sareum closer to the commercialisation of drug
candidates from our in-house development pipeline. We are currently actively
seeking to license these programmes in order to allow us to drive forward other
programmes that have been generated from our SKIL platform.

The placings during the course of the year, which raised a total of GBP950,000,
have provided us with sufficient working capital for the foreseeable future to
continue the current level of development of our in-house programmes."